Eisai China successfully held “2019 ADS Beijing “
On October 19, 2019, the “2019 ADS Beijing” sponsored by Eisai China Inc. was held in Beijing, which is another platform for doctors’ information exchanges. Featuring the theme of “Let’s Build Hope Together”, the main forum and three sub-forums focused on the latest cutting-edge academic research and clinical practice and development in China and in the world. 37 well-known experts and scholars from China, Japan, Singapore, Spain and other countries, more than 300 on-site guests and nearly 1,000 on-line guests jointly discussed and conducted dialogues and interactions, producing collision of ideas and academic resonance between China and foreign countries.
At the beginning of the summit, Mr. Zhang Jianzhong, VP and Head of Pharmaceutical Business Division of Eisai China Inc., delivered a speech. Firstly, Mr. Zhang gave a warm welcome to all the experts and guests and sincerely thanked them for their strong support to the 2019 ADS Beijing Summit. Eisai China Inc. will devote itself to building an academic exchange platform for cognitive disorders and continue to increase research and development of new drugs in this field. At the same time, adhering to its business philosophy of hhc (human health care), it will work hand in hand with all walks of life to make contributions in the cognition, prevention and control of diseases, patient care and other aspects.
Zhang Jianzhong delivered a speech
At this summit, Professor Jianping Jia and Professor Luning Wang were invited to act as chairmen of the summit. Both of Professor Jia and Professor Wang expressed their thanks to Eisai China Inc. for setting up such an academic exchange platform to allow experts from many countries and guests to share academic and clinical practice and to jointly explore new modes of control and prevention of diseases in the field of cognitive impairment, and wished the summit a complete success.
A group photo of some experts
In the main forum, experts held academic discussions on issues such as the development of cognitive science, researches on the post-stroke cognitive impairment, researches on self-management of patients with Alzheimer’s disease, the comparison of CSF and blood biomarkers for Alzheimer disease, researches on DLB and PDD drugs, advances and clinical treatment experiences of VAD. They also held large-scale discussions on issues such as sleep and cognitive impairment, non-invasive biomarkers, and new target drugs for treatment of Alzheimer’s disease, colliding their ideas and benefiting the participants.
Photo of main forum
In the “practice” sub-venue, the themes were “Measurement”, “Observation”, “Investigation”, “Differentiation “, Identification”, “Treatment” and “Practice”. Speeches and case discussions and “on-the-spot consultation” mode discussions were conducted on the clinical applications of neurocognitive assessment, AD picture description, new progress in gene diagnosis of Chinese population, truth and falsehood of senile depression “pseudodementia”, sharing of DLB or AD difficult cases, AD whole-process management and rational drug use. In the “field hotspots” sub-venue, from theory to practice, the participants interpreted in detail the “China Guidelines for Cognitive Impairment Related to Cerebral Small Vessels (2019)”, “China Expert Consensus on Post-stroke Cognitive Impairment Rehabilitation” and “Outpatient Management Standard for Patients with Post-stroke Cognitive Impairment”, and shared their experience and practical theories. In the “Care for Patients with Alzheimer’s Disease in All Aspects” sub-venue, the participating experts shared and discussed the contents in three aspects: exploring a new management model for Alzheimer’s disease, scientific care, and social support. The topics covered the medical care models based on family needs in Shanghai, management system for patients with Alzheimer’s disease, community two-way referral model, clinical characteristics and care needs of patients with Alzheimer’s disease, setting of care plans and case analysis for the mentally retarded elderly, and consideration of long-term care for the elderly by the commercial insurance industry. In the exchanges and collision of opinions, the latest academic frontier progress and clinical practice experience were shared.
Based on more than 35 years of drug research and development experience in the fields of Alzheimer’s disease and dementia, Eisai strives to realize the prevention and treatment of dementia through multidimensional and comprehensive methods. Every year, many academic exchange activities sponsored by Eisai China Inc., such as Empowering Neurology’s Future (ENF), Peripheral Neuropathy Summit (PNS) and ADS Beijing Summit, have become brands that are recognized and highly praised by doctors. Eisai China Inc. will always adhere to the philosophy of “hhc (human health care)” that “we give first thought to patients and their families, and to increasing the benefits health care provides. ” While providing disease solutions, it also provides long-term communication and learning platforms for medical professionals, and builds bridges for the exchanges of latest medical information at home and abroad.